A partially-blind phase III randomised trial of fulvestrant (Faslodex™) with or without concomitant anastrozole (Arimidex™) compared with exemestane in post-menopausal women with oestrogen receptor (ER) positive locally advanced/metastatic breast cancer following progression on non-steroidal aromatase inhibitors

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2003
This article has no abstract
Epistemonikos ID: bde000b2dc08ef31323cd4e32dfc6ef22c95c2f7
First added on: Jan 17, 2025